Shire plc sells its oncology business to Servier

Shire plc the leading global biotechnology company focused on rare diseases announces that it has entered into a definitive agreement with Servier S.A.S. to sell its Oncology business for $2.4 billion. Shire�s Oncology business includes in-market products Oncaspar (pegaspargase), a component of multi-agent treatment for acute lymphoblastic leukemia (ALL) and ex-U.S. rights to Onivyde (irinotecan pegylated liposomal formulation), a component of multi-agent treatment for metastatic pancreatic cancer post gemcitabine-based therapy. The portfolio also includes Calaspargase Pegol (Cal-PEG), which is under FDA review for the treatment of ALL and early stage immuno-oncology pipeline collaborations.